Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

anagrelide

×

Overview

What is anagrelide?

Anagrelide hydrochloride, USP is a platelet-reducing agent. Its chemical name is 6,7-dichloro-1,5 dihydroimidazo[2,1-b] quinazolin-2(3H)-one monohydrochloride monohydrate and it has the following structural formula:

CHClNO·HCl·HO M.W. 310.56

Anagrelide hydrochloride, USP is a white to off white powder that is practically insoluble in water and slightly soluble in dimethyl sulfoxide and very slightly soluble in dimethylformamide.

Each Anagrelide Capsule USP, for oral administration, contains either 0.5 mg or 1 mg of anagrelide as anagrelide hydrochloride, USP and has the following inactive ingredients: black iron oxide, gelatin, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, hydroxylpropyl cellulose, propylene glycol, shellac and titanium dioxide, potassium hydroxide.



What does anagrelide look like?



What are the available doses of anagrelide?

Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.

Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having white opaque cap and white opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.

What should I talk to my health care provider before I take anagrelide?

How should I use anagrelide?

Anagrelide is a platelet reducing agent indicated for the treatment of thrombocythemia, secondary to myeloproliferative neoplasms, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events. (1)

Adults: The recommended starting dosage of anagrelide capsules is 0.5 mg four times daily or 1 mg twice daily.

Pediatric Patients: The recommended starting dosage of anagrelide capsules is 0.5 mg daily.


What interacts with anagrelide?

Sorry No Records found


What are the warnings of anagrelide?

Sorry No Records found


What are the precautions of anagrelide?

Sorry No Records found


What are the side effects of anagrelide?

Sorry No records found


What should I look out for while using anagrelide?

None (4)


What might happen if I take too much anagrelide?

At higher than recommended doses, this medicine has been shown to cause hypotension. There have been postmarketing case reports of intentional overdose with anagrelide hydrochloride. Reported symptoms include sinus tachycardia and vomiting. Symptoms resolved with supportive management. Platelet reduction from anagrelide therapy is dose-related; therefore, thrombocytopenia, which can potentially cause bleeding, is expected from overdosage.

In case of overdosage, close clinical supervision of the patient is required; this especially includes monitoring of the platelet count for thrombocytopenia. Dosage should be stopped, as appropriate, until the platelet count returns to within the normal range.


How should I store and handle anagrelide?

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Preserve in tight, light-resistant containers as defined in the USP.Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Preserve in tight, light-resistant containers as defined in the USP.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.Anagrelide capsules, USP 0.5 mg are Size '4', hard gelatin capsule having grey opaque cap and white opaque body, imprinted '1453' on cap and '0.5 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-453-30Bottles of 100                                                    NDC 13668-453-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-453-74Anagrelide capsules, USP 1 mg are Size '3', hard gelatin capsule having White opaque cap and White opaque body, imprinted '1462' on cap and '1 mg' on body with black ink containing white to off-white powder.Bottles of 30                                                      NDC 13668-462-30Bottles of 100                                                    NDC 13668-462-01Carton of 100 capsules (10 x 10 unit-dose)      NDC 13668-462-74Store at 20 to 25C (68 to 77F); excursions permitted between 15C and 30C (59F and 86F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container with a child-resistant closure (as required).KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

The precise mechanism by which anagrelide reduces blood platelet count is unknown. In cell culture studies, anagrelide suppressed expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.

Non-Clinical Toxicology
None (4)

Cyclobenzaprine HCl may have life-threatening interactions with MAO inhibitors. (See .) Postmarketing cases of serotonin syndrome have been reported during combined use of Cyclobenzaprine Hydrochloride and other drugs, such as SSRIs, SNRIs, TCAs, tramadol, bupropion, meperidine, verapamil, or MAO inhibitors. If concomitant treatment with Cyclobenzaprine Hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see ).

Cyclobenzaprine HCl may enhance the effects of alcohol, barbiturates, and other CNS depressants.

Tricyclic antidepressants may block the antihypertensive action of guanethidine and similarly acting compounds.

Tricyclic antidepressants may enhance the seizure risk in patients taking tramadol. 

† ULTRAM (tramadol hydrochloride tablets, Ortho-McNeil Pharmaceutical)

† ULTRACET (tramadol hydrochloride and acetaminophen tablets, Ortho-McNeil Pharmaceutical)

Torsades de pointes and ventricular tachycardia have been reported with anagrelide. Obtain a pre-treatment cardiovascular examination including an ECG in all patients. During treatment with anagrelide monitor patients for cardiovascular effects and evaluate as necessary.

Anagrelide increases the QTc interval of the electrocardiogram and increases the heart rate in healthy volunteers [see

Do not use anagrelide in patients with known risk factors for QT interval prolongation, such as congenital long QT syndrome, a known history of acquired QTc prolongation, medicinal products that can prolong QTc interval and hypokalemia

Hepatic impairment increases anagrelide exposure and could increase the risk of QTc prolongation. Monitor patients with hepatic impairment for QTc prolongation and other cardiovascular adverse reactions. The potential risks and benefits of anagrelide therapy in a patient with mild and moderate hepatic impairment should be assessed before treatment is commenced. Reduce anagrelide dose in patients with moderate hepatic impairment. Use of anagrelide in patients with severe hepatic impairment has not been studied [

In patients with heart failure, bradyarrhythmias, or electrolyte abnormalities, consider periodic monitoring with electrocardiograms

Anagrelide is a phosphodiesterase 3 (PDE3) inhibitor and may cause vasodilation, tachycardia, palpitations, and congestive heart failure. Other drugs that inhibit PDE3 have caused decreased survival when compared with placebo in patients with Class III-IV congestive heart failure

In patients with cardiac disease, use anagrelide only when the benefits outweigh the risks.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).